AI Summary
✦ ClarthaValuation Metrics
Trading 66.3% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +3.36). Confidence: 83%.
Live forward EPS implies next-12-month EPS of ₹19.35. Applying the stock's normalized valuation corridor produces a fair range of ₹736.46 to ₹922.22, with base value near ₹799.35 (-27.8% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹19.35
Forward P/E
57.2x
Base Fair Value
₹799.35
Fair Range
₹736.46 - ₹922.22
Upside To Base
-27.8%
Estimate Source
Live forward EPS
Growth Estimate
+28.2%
5Y Average
46.36
Current
68.71
Overvalued
47.66
Undervalued
38.06
5Y Average
36.47
Current
54.05
Overvalued
41.36
Undervalued
29.69
5Y Average
12.48
Current
18.50
Overvalued
14.16
Undervalued
10.17
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 28.6x Undervalued | -46% vs avg | +15.8% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 169.5x Premium | +217% vs avg | -51.4% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.1x Undervalued | -47% vs avg | +44.2% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 39.5x Undervalued | -26% vs avg | +59.3% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.9x Undervalued | -18% vs avg | -25.1% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Undervalued | -29% vs avg | -15.4% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 39.9x Undervalued | -25% vs avg | +29.3% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 39.9x Undervalued | -25% vs avg | +31.8% |
SUDEEP PHARMA LIMITED trades at a premium (68.3x vs peer avg 53.4x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include CAPLIN POINT LAB LTD., COHANCE LIFESCIENCES LTD, ALIVUS LIFE SCIENCES LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹90 CrDec 2025Latest net profit
₹27 CrDec 2025Latest EPS
₹2.42Dec 2025Net margin
30.8%Dec 2025Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Dec 2025
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|
| Sales | 106 | 83.48 | 80.17 | 87.88 | 90.28 |
| Expenses | 66.09 | 57.02 | 49.77 | 57 | 60.67 |
| Operating Profit | 38.74 | 24.93 | 28.65 | 29.11 | 27.82 |
| OPM % | 36.44% | 29.86% | 35.74% | 33.12% | 30.82% |
| Other Income | 1.44 | 2.29 | 6.62 | 12.83 | 9.44 |
| Interest | 0.71 | 1.25 | 1.44 | 2.03 | 0.63 |
| Depreciation | 1.47 | 1.53 | 1.75 | 1.77 | 1.79 |
| Profit before tax | 39.47 | 25.97 | 33.83 | 39.91 | 36.63 |
| Tax % | 25.39% | 20.56% | 25.51% | 25.48% | 26.64% |
| Net Profit | 29.45 | 20.63 | 25.2 | 29.74 | 26.87 |
| EPS in Rs | 2.71 | 1.90 | 2.29 | 2.67 | 2.42 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.